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ABSTRACT (248 words) 
Purpose:  
To assess the effect of venovenous extracorporeal membrane oxygenation (ECMO) compared to 
conventional management in patients with severe acute respiratory distress syndrome (ARDS). 
Methods: 
We conducted a systematic review and individual patient data meta-analysis of randomised 
controlled trials (RCTs) performed after Jan 1, 2000 comparing ECMO to conventional management 
in patients with severe ARDS. The primary outcome was 90-day mortality. Primary analysis was by 
intent-to-treat.  
Results: 
We identified two RCTs (CESAR and EOLIA) and combined data from 429 patients. On day 90, 77 
of the 214 (36%) ECMO-group and 103 of the 215 (48%) control group patients had died (relative 
risk (RR), 0.75, 95% confidence interval (CI), 0.60–0.94; P=0.013; I2=0%). In the per-protocol and 
as-treated analyses the RRs were 0.75 (95% CI, 0.60–0.94) and 0.86 (95% CI, 0.68–1.09), 
respectively. Rescue ECMO was used for 36 (17%) of the 215 control patients (35 in EOLIA and 1 
in CESAR). The RR of 90-day treatment failure, defined as death for the ECMO-group and death or 
crossover to ECMO for the control group was 0.65 (95% CI, 0.52–0.80; I2=0%). Patients randomised 
to ECMO had more days alive out of the ICU and without respiratory, cardiovascular, renal and 
neurological failure. The only significant treatment-covariate interaction in subgroups was lower 
mortality with ECMO in patients with two or less organs failing at randomization.  
Conclusions: 
In this meta-analysis of individual patient data in severe ARDS, 90-day mortality was significantly 





Take home message 
In this meta-analysis of individual patient data in severe ARDS, 90-day mortality was significantly 
lowered by ECMO compared with conventional management. Patients randomised to ECMO had 




ECMO significantly lowered 90-day mortality compared with conventional management in this 





Ventilatory management of patients with severe acute respiratory distress syndrome (ARDS) has 
improved over the last decades with a strategy combining low tidal volume (VT) ventilation,[1] high 
positive end-expiratory pressure (PEEP),[2, 3] neuromuscular blocking agents[4] and prone 
positioning.[5] However, ventilator-induced lung injury (VILI) may persist in these patients since a 
recent and large epidemiological study showed that their hospital mortality was still 46%.[6] 
Recently, even higher mortality was reported for patients with severe acute respiratory syndrome 
coronavirus2 (SARS-CoV-2) infection who needed invasive mechanical ventilation.[7-9]  
Venovenous extracorporeal membrane oxygenation (ECMO) providing full blood 
oxygenation, CO2 elimination and combined with more gentle ventilation has benefited from major 
technological advances in the last 15 years.[10, 11] In 2009, favourable outcomes were reported in 
patients who received ECMO during the influenza A (H1N1) pandemic.[12-14] The Conventional 
Ventilator Support vs Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Failure 
(CESAR) trial[15, 16] showed that transfer to an ECMO centre was associated with fewer deaths or 
severe disabilities at 6 months compared with conventional mechanical ventilation (37% vs. 53%; p 
0 = 0.03), although 6 month mortality was not significantly reduced (37% vs. 45%; p = 0.07). The 
more recent ECMO to Rescue Lung Injury in Severe ARDS (EOLIA) trial showed a non-statistically 
significant reduction in 60-day mortality with ECMO (35% vs. 46%; p = 0.09).[17] However, neither 
trial was separately powered to detect a 10-15% survival benefit with ECMO.  
We performed a systematic review with an individual patient data meta-analysis of 
randomised controlled trials comparing ECMO to conventional mechanical ventilation in patients 
with severe ARDS. The primary objective was to evaluate the effect of ECMO on 90-day mortality. 
Secondary objectives included the evaluation of ECMO for other clinical outcomes and in pre-






This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic 
reviews and Meta-Analyses for Individual Patient Data (PRISMA-IPD checklist in eTable 1 in the 
Supplement) and the protocol was registered in PROSPERO (CRD42019130034).  
 
Eligibility criteria 
We included all randomised controlled trials (RCTs) evaluating venovenous ECMO in the 
experimental group and conventional ventilatory management in the control group, that included 
patients with ARDS fulfilling the American–European Consensus Conference definition[18] or the 
Berlin definition for ARDS,[19] and that were published or whose primary completion date was after 
2000.[10, 20, 21] This choice was justified by the major improvements in intensive care treatments 
and in ECMO technology that occurred in the last two decades. Additional information on selection 
criteria is provided in the Supplement.  
 
Search strategy 
We searched MEDLINE via PubMed, EMBASE and the Cochrane Central Register of Controlled 
Trials (Central) from January 1, 2000 to September 30, 2019 using a search algorithm developed for 
the purpose of this study and adapted to each database (eTable 2 in the Supplement). We also 
searched trial registries including ClinicalTrials.gov and the International Clinical Trial Registry 
Platform (ICTRP) for completed and ongoing trials, conference proceedings of major critical care 
societies and screened reference lists of identified articles as well as systematic or narrative reviews 
on the topic (see the Supplement). 
 
Selection and data collection 
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Selection was conducted independently by two reviewers (DA and MS) on titles and abstracts first 
and then, on the full text. For each included RCT, the corresponding author was contacted to provide 
fully anonymized individual patient data as well as format, coding and definition of any variables. 
Risk of bias in each trial was evaluated by two independent reviewers (DH and AD) using the 
updated version of the risk-of-bias tool developed by Cochrane[22] (see the Supplement).  
 
Study outcomes 
The primary endpoint was mortality 90 days after randomisation. Main secondary endpoints 
comprised time to death up to 90 days after randomisation, treatment failure up to 90 days, defined 
as crossover to ECMO or death for patients in the control group, and death for patients in the ECMO 
group, number of days alive and out-of-hospital between randomisation and day 90, number of days 
alive without mechanical ventilation, renal replacement therapy and vasopressor support between 
randomisation and day 90. Other preplanned secondary outcomes comprised mortality at 28 and 60 
days after randomisation, number of days alive and out of the ICU between randomisation and day 
90, number of days alive without respiratory failure, neurological failure, cardiovascular failure, liver 
failure, renal failure and coagulation failure, defined as the corresponding component sequential 
organ failure assessment (SOFA) score greater than 2 between randomisation and day 90. Data 




The statistical analysis was performed for each outcome of interest using individual patient data. An 
intention-to-treat analysis was used for all outcomes, whereby all patients were analysed in the 
groups to which they were randomised. The measures of treatment effect were risk ratios for binary 
outcomes, hazard ratios for time-to-event outcomes and mean differences for quantitative outcomes. 
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The primary endpoint was defined as a binary outcome and analysed using both one-step (as primary 
analysis) and two-steps (as sensitivity analysis) methods.[23] In the one-step method, we analysed 
both studies simultaneously to obtain the combined treatment effect with 95% CIs and p-value by 
using a generalized linear mixed effect model to account for the clustering of data within each trial 
with a random effect. In the two steps method, we first analysed separately each trial using individual 
patient data before combining them using a random effects meta-analysis model to account for 
variability between studies. A two-step method was used for all secondary outcomes. Heterogeneity 
was evaluated with the Cochran's Q-test, I2 statistic and between study variance 2. Survival curves 
for the time to death up to 90 days were generated using individual patient data and the Kaplan-
Meier method.  
We conducted sensitivity analyses for the primary outcome in different populations (per-protocol, as-
treated). The per-protocol population included all randomised patients having received the treatment 
attributed by randomisation (i.e., patients having received ECMO in the ECMO arm and patients not 
having received ECMO in the control arm). The as-treated population compared patients receiving 
ECMO to those who did not receive ECMO, whatever the randomisation arm. A sensitivity analysis 
excluding trials at high risk of bias was also planned.  
We explored whether the effect of ECMO on 90-day mortality varied according to baseline patient 
characteristics (see the Supplement). For each subgroup, the treatment-subgroup interaction was 
tested in the one-step model. For quantitative baseline characteristics, we used the median values to 
define the subgroups. All these subgroup analyses were pre-planned (PROSPERO, 
CRD42019130034). 
Alpha risk was set at 5% for the primary outcome. For all secondary outcomes, we did not correct for 
multiple testing. As such, subgroup and sensitivity analyses should be considered as exploratory. All 
the analyses were performed with the use of R software version 3.6.1 (R Foundation). 
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The quality of evidence for the 7 most important outcomes was graded with GRADEpro GDT 
(GRADEpro GDT: GRADEpro Guideline Development Tool [Software]; McMaster University, 
2015 (developed by Evidence Prime, Inc.; Available from gradepro.org). 
 
Results 
Selection process and general characteristics 
From the 1179 references identified by the search strategy, we included two randomised controlled 
trials fulfilling our eligibility criteria – CESAR and EOLIA.[15, 17] Reasons for exclusion are 
reported in eFigure 1 of the Supplement. The two trials provided individual patient data for all 
randomised patients (429 overall, 180 in CESAR and 249 in EOLIA), and there was no eligible trial 
not providing individual patient data. Detailed characteristics of the two trials are reported in eTable 
3 in the Supplement.  
Comparison of patient characteristics at randomisation did not show baseline imbalance between 
groups (Table 1 and eTable 4 and 5 in the Supplement). The main disorder leading to study entry 
was severe hypoxia (in 88% of the patients, with a mean (±SD) PaO2:FIO2 of 75±34 mm Hg). The 
main cause of ARDS was pneumonia (>60% of the patients) and 39% had 3 or more organs failing at 
randomisation. Of the 214 patients randomised to the ECMO groups, 189 (88%) received ECMO 
(98% and 76% in EOLIA and CESAR, respectively). Rescue extracorporeal gas exchange was used 
for 36 (17%) of the 215 control patients (35 patients crossed over to ECMO in EOLIA, and 1 to 
pumpless arteriovenous CO2 removal in CESAR that was a protocol violation by the conventional 
management team as rescue extracorporeal gas exchange was not part of the CESAR trial design). 





By day 90, 77 (36%) ECMO-group and 103 (48%) control group patients had died (relative risk, 
0.75, 95% confidence interval, 0.60 to 0.94; p = 0.013) (Table 2 and Figure 1). Results were similar 
in the one-step and two-steps models. There was no evidence of heterogeneity across studies (p = 
0.640, I2=0%, τ2=0.000).  
 
Secondary Outcomes 
The hazard ratio for death within 90 days after randomisation in the ECMO group, as compared with 
the control group, was 0.65 (95% CI, 0.49 to 0.88) (Fig. 2). The relative risk of treatment failure, 
defined as death by day 90 for the ECMO-group and death or crossover to ECMO for the control 
group was 0.65 (0.52 to 0.80) (Table 2 and eFigure 3 in the Supplement). At 90 days, ECMO-group 
patients had more days alive without ventilation (40 vs 31 days, mean difference, 8 days; 95% CI, 2 
to 15) and out of the ICU (36 vs 28 days, mean difference, 8 days; 95% CI, 2 to 14) than those in the 
control group (Table 2 and eFigure 4 in the Supplement).  
At day 60 post-randomisation (90-day follow-up was not available for the following outcomes in 
EOLIA), patients in the ECMO group had more days alive without vasopressors (35 vs 28 days, 
mean difference, 8 days; 95% CI, 3 to 13), renal replacement therapy (35 vs 28 days, mean 
difference, 7 days; 95% CI, 2 to 13) and neurological failure (38 vs 31 days, mean difference, 7 days; 
95% CI, 2 to 13) than those in the control group (Table 2 and eFigure 5 in the Supplement). Prone 
positioning and low-volume low-pressure mechanical ventilation were applied to 71% and 85% of 
control group patients, respectively (Table 3). Multiorgan failure and respiratory failure were the 
main causes of death in both groups (Table 3), while a cannulation-related fatal complication 
occurred in 3 of the 225 patients who received ECMO. Of the 214 patients randomised to ECMO, 7 
(3%) died before ECMO could be established. Additional data on secondary outcomes are provided 




Sensitivity and subgroup analyses 
The relative risks of death at day 90 post-randomisation according to the per-protocol and as-treated 
analyses were 0.75 (95% CI, 0.60 to 0.94) and 0.86 (95% CI, 0.68 to 1.09), respectively (eFigure 7 in 
the Supplement). The only significant treatment-covariate interaction identified in subgroup analyses 
was the number of organs failing at randomisation with RR=0.53 (95% CI 0.36-0.78) among patients 
with 1-2 organ failures and RR=1.00 (95% CI 0.78-1.30) among patients with 3 or more organ 
failures, p = 0.006 for interaction (Figure 3). There was no evidence to suggest a differential 
treatment effect for any other subgroups. 
 
Quality of Evidence 
The Summary Of Findings Table reporting the evaluation of the quality of evidence for the 7 most 
important outcomes is presented in eTable 6 in the Supplement. The level of evidence was high for 
mortality at 90 days, time to death and treatment failure. 
 
Discussion  
In this individual patient data meta-analysis of patients with severe ARDS included in the 
CESAR[15] and EOLIA[17] randomised trials, there is strong evidence to suggest that early recourse 
to ECMO leads to a reduction in 90-day mortality and less treatment failure compared with 
conventional ventilatory support. Patients randomised to ECMO also had more days alive out of the 
ICU and without respiratory, cardiovascular, renal and neurological failure.  
 The benefit of ECMO in severe ARDS patients has long been debated.[24-27] Because of highly 
challenging design and conduct issues, only four randomised trials of extracorporeal life support for 
adult patients with acute respiratory failure have been performed in the last 5 decades.[15, 17, 28, 29] 
Our meta-analysis included only the two most recent trials (CESAR[15] and EOLIA[17]) since 
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major advances in ICU care and in ECMO techniques have occurred in the past 15 years making the 
two older trials not relevant for comparison.[10, 20, 21] In addition the two older trials did not use 
venovenous ECMO. One used venoarterial ECMO[28] and one used low-flow veno-venous 
extracorporeal CO2 removal.[29] Characteristics of patients included in EOLIA and CESAR were 
comparable regarding ARDS aetiology and disease severity at randomisation. Patients were enrolled 
early after the initiation of invasive mechanical ventilation and rates of control patients being proned 
and receiving low-volume low-pressure mechanical ventilation were high. Both EOLIA and CESAR 
trials showed a comparable survival benefit with ECMO, but neither was individually powered to 
detect a reasonable survival difference between groups. Specifically, the data safety monitoring 
board of EOLIA, following pre-specified guidance using a sequential design with a two-sided 
triangular test based on 60-day mortality, recommended stopping the trial for futility after 75% of the 
maximal sample size had been enrolled because the probability of demonstrating a 20% absolute risk 
reduction in mortality with ECMO was considered unlikely. Our meta-analysis, which includes a 
much larger number of patients and shows higher survival with ECMO in both the intention-to-treat 
and per-protocol analyses provides strong evidence about the benefit of ECMO in severe ARDS. Our 
results also extend the conclusions of a post-hoc Bayesian analysis of EOLIA indicating a very high 
probability of ECMO success in severe ARDS patients, ranging from 88% to 99% depending on the 
chosen priors.[30] Our results are consistent with two previous aggregated data meta-analyses in the 
field: one was a network meta-analysis considering different interventions whose impact is limited 
by the lack of direct comparisons[31] and the other focused on ECMO.[32] Our IPD meta-analyses 
goes beyond these two previous studies and provides a stronger evidence on the benefit of ECMO in 
ARDS for the following reasons. IPD meta-analyses provides a higher level of evidence than 
aggregated data meta-analyses because they are independent of the quality of reporting in included 
studies and allow evaluation of other important outcomes such as time to death and number of days 
without organ failures.[33, 34] 
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 In this study, we showed that, beyond mortality, duration and severity of organ failures also 
favoured ECMO, and these results were highly consistent between the two studies. This observation 
provides insights into the potential pathophysiological mechanisms of ECMO-associated benefits in 
severe ARDS.[10] Although extracorporeal gas exchange may rescue some patients dying of 
profound hypoxemia or in whom high pressure mechanical ventilation has become dangerous, 
minimization of lung stress and strain associated with positive pressure ventilation may drive most of 
the improved outcomes observed under ECMO.[10] Ultraprotective ventilation with very low VTs, 
driving pressures and respiratory rates,[35] and therefore minimized overall mechanical power 
transmitted to lung alveoli[36] may reduce ventilator-induced lung injury, pulmonary and systemic 
inflammation and ultimately organ failure leading to death. These data also reinforce the recent 
recommendation of the World Health Organization (WHO),[37] and the Surviving Sepsis 
Campaign[38] to consider ECMO support in coronavirus disease 2019 (COVID-19)-related ARDS 
with refractory hypoxemia if lung protective mechanical ventilation was insufficient to support the 
patient.[39] 
 Meta-analyses of individual patient data can also explore outcomes in important subgroups and 
suggest which population may derive the greatest benefit of a specific intervention, which is very 
limited in aggregated data meta-analyses.[40] In this study, the mortality of patients with only one or 
two organs failing at randomisation was almost halved with ECMO (22% vs. 41%) while it was not 
substantially different between groups in patients with ≥3 organ failures. This finding suggests that 
veno-venous ECMO may not be able to improve the outcomes of ARDS patients with severe shock 
and multiple organ failure. In EOLIA, patients with baseline PaO2:FIO2 >66 mmHg or those enrolled 
due to severe respiratory acidosis and hypercapnia, seemed to derive the greatest benefit of 
ECMO.[17]  
 This analysis has several limitations. First, inclusion criteria were more stringent for the EOLIA 
trial, in which, for example, ventilator optimization (FIO2>80%, VT at 6 ml/kg predicted body 
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weight and PEEP >10 cm H2O) was mandatory before enrolment. However, it should be noted that 
baseline patient characteristics were comparable regarding ARDS severity at inclusion (eTable 4 in 
the Supplement). Second patient management was not similar in the two studies. In CESAR, 24% of 
patients randomised to the ECMO arm did not receive ECMO and there was no standardized 
protocol for mechanical ventilation in the control group. Conversely, in EOLIA, 98% of patients 
randomised to ECMO received the intervention, the mechanical ventilation strategy in the control 
group followed a strict protocol, and rescue ECMO was applied to 28% of control group patients 
who had developed refractory hypoxemia. However, this meta-analysis showed a significantly lower 
mortality with ECMO in the per-protocol analysis including only patients in whom ECMO had been 
initiated in the ECMO arm and patients not having ECMO in the control arm. This analysis 
minimizes the aforementioned management differences, since the least severe patients who did not 
receive ECMO after MV optimization in CESAR were excluded from the ECMO arm and the most 
severe patients who needed rescue ECMO in EOLIA were excluded from the control arm. In 
contrast, ECMO was not associated with a mortality benefit in the as-treated population, but such an 
analysis strongly disadvantages the ECMO group, which includes the most severe control patients 
rescued by ECMO. Second, this meta-analysis does not provide detailed data on ECMO-related 
safety endpoints since they were not reported in CESAR. Death directly related to ECMO 
cannulation was rare in both studies and the rates of stroke and major bleeding were also low in 
EOLIA, in which a restrictive anticoagulation strategy was applied.[17] Third, no long-term 
outcomes beyond 90 days post-randomisation were analysed although the CESAR trial[15] and a 
retrospective cohort of ARDS patients[41] reported satisfactory long-term health-related quality-of-
life after ECMO. Fourth, only the CESAR trial provided a cost-effectiveness analysis that suggested 
a benefit of the transfer of ARDS patients to a centre with an ECMO-based management 
protocol.[15] Our results, showing improved survival, with more days alive out of the ICU and 
without the need for major organ support are in line with CESAR’s cost-effectiveness data. Fifth, 
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many conditions such as MV duration >7 days prior to ECMO or major comorbidities were 
exclusion criteria for enrolment in both CESAR and EOLIA. The indication to initiate ECMO should 
therefore be carefully evaluated in these situations. Lastly, ECMO should be used in experienced 
centres and only after proven conventional management of severe ARDS (including lung protective 
mechanical ventilation and prone positioning) have been applied and failed,[42] except when 
hypoxemia is immediately life-threatening, or when the patient is too unstable for prone 
positioning.[43] 
 In conclusion, this meta-analysis of individual patient data of the CESAR and EOLIA trials 
showed strong evidence of a clinically meaningful benefit of early ECMO in severe ARDS patients. 
Another large study of ECMO appears unlikely in this setting and future research should focus on the 
identification of patients most likely to benefit from ECMO and optimization of treatment strategies 




The trial was registered at PROSPERO (CRD42019130034) on May 1st 2019. 
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(N = 214) 
Control group 
(N = 215) 
Age, years 46.6±15.2 48.3±14.8 
Male — no. (%) 138 (65) 143 (67) 
Median (interquartile) time since intubation, h  35 [16-95] 36 [16-100] 
ARDS aetiology — no. (%)   
Pneumonia 136 (64) 131 (61) 
Other 78 (36) 84 (39) 
3 or more organs failed† 82 (38) 84 (39) 
Predicted mortality‡ 0.34±0.23 0.34±0.22 
PaO2:FIO2 76±35 75±33 
pH 7.30±0.37 7.26±0.24 
Disorder leading to study entry   
Hypoxia 184 (86%) 192 (89%) 
Uncompensated hypercapnia 30 (14%) 23 (11%) 
PEEP, cm H2O 12.3±6.8 12.7±6.8 
Respiratory system compliance, ml/cm H2O 25.8±11.8 25.3±8.8 
Murray Score 3.3±0.6 3.3±0.4 
Chest radiograph (quadrants infiltrated) 3.4±0.9 3.5±0.8 
 
* Plus–minus values are means ±SD; see eTable 5 the Supplement for missing data.  
† number of organ failed (0 to 6) defined as the corresponding component sequential organ failure 
assessment (SOFA) score > 2. 




ECMO denotes extracorporeal membrane oxygenation, ARDS the acute respiratory distress 
syndrome, PaO2 partial pressure of arterial oxygen, FiO2 the fraction of inspired oxygen, PaO2/FIO2 
the ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen, PEEP positive 
end-expiratory pressure.  
Missing data were <3% for patients’ characteristics at randomisation, except for predicted mortality, 
respiratory system compliance and Murray score (see eTable 5 in the Supplement). 
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(N = 214) 
Control  
group 
(N = 215) 
Relative Risk or 
difference 
(95% CI) 
P  I2 
(%) 
Primary endpoint      
 Day 90 mortality — no. (%) 77 (36) 103 (48) 0.75 (0.60 to 0.94) 0.013 0 
Secondary endpoints*      
 Day 90 treatment failure — no. (%) 77 (36) 119 (55) 0.65 (0.52 to 0.80)  0 
 Day 28 mortality — no. (%) 50 (23) 88 (41) 0.57 (0.40 to 0.81)  33 
 Day 60 mortality — no. (%) 73 (34) 101 (47) 0.73 (0.58 to 0.92)  0 
 Day 1–90 ICU-free days † 36±32 28±33 8 (2 to 14)  0 
 Day 1–90 hospital-free days † 22±27 18±27 4 (-1 to 9)  0 
 Day 1–90 ventilation-free days † 40±35 31±34 8 (2 to 15)  0 
 Day 1–60 vasopressor-free days †‡ 35±26 28±27 8 (3 to 13)  0 
 Day 1–60 RRT-free days †‡ 35±27 28±27 7 (2 to 13)  0 
 Day 1–60 neurological failure-free days †‡£ 38±28 31±30 7 (2 to 13)  6 
 
Data are mean (SD) or number (%). 
ECMO denotes extracorporeal membrane oxygenation, ICU intensive care unit and RRT renal 
replacement therapy.  
* The width of confidence intervals have not been adjusted for multiplicity and should not be used to 
infer definitive treatment differences.  
† Free-days were calculated assigning zero free-days to patients who died during the follow-up 
period. 
‡ Day-by-day follow-up was limited to Day 60 in the EOLIA trial 
£ Neurological failure was defined by the number of days without neurological depression requiring 
system monitoring/support' in CESAR study and the neurologic component of the sequential organ 









(N = 214) 
Control group 
(N = 215) 
 Received ECMO — no. (%) 189 (88) 36 (17) 
 Days under ECMO* 14.3±12.6 16.6±15.0 
 Received LVLP MV — no. (%)† 205 (98) 181 (85) 
 Prone position (before and after 
randomisation) — no. (%)† 
114 (54) 151 (71) 
 iNO or prostacyclin — no. (%)† 84 (40) 110 (51) 
 Renal replacement therapy — no. (%)† 106 (50) 129 (60) 
 Steroids — no. (%)† 156 (74) 140 (65) 
 ICU length of stay, days 29.7±24.6 23.6±35.9 
For survivors 35.2±22.5 39.5±26.3 
For non-survivors 20.2±17.6 15.4±16.2 
 Hospital length of stay, days 49.0±43.1 42.7±69.3 
For survivors 58.3±23.8 60.0±28.5 
For non-survivors 20.2±17.6 15.4±16.2 
 Cause of death   
 Respiratory failure 13 (6) 36 (17) 
 Multiple organ failure 35 (16) 44 (20) 
 ECMO cannulation-related 2 (1) 1 (0) 
 Miscellaneous 27 (13) 22 (10) 
 
Data are mean (SD) or number (%); see eTable 5 in the Supplement for missing data. 
* For patients who received ECMO. 
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† From randomisation to Day 60. 
ECMO denotes extracorporeal membrane oxygenation, LVLP MV, low-volume low-pressure 
mechanical ventilation, iNO inhaled nitric oxide, and ICU intensive care unit.  





Figure 1. Forest plot of 90-day mortality in the intention-to-treat population. 
 
Figure 2. Kaplan–Meier survival estimates in the intention-to-treat population of the time to 
death within the first 90 study days. 
 
Figure 3. Subgroup analyses for the primary outcome according to baseline characteristics. 
MV, mechanical ventilation; number of organ failed (0 to 6) defined as the corresponding component 
sequential organ failure assessment (SOFA) score > 2; APACHE2 (CESAR) and SAPS2 (EOLIA) 
scores were both translated to predicted probability of ICU mortality. 
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